Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Published:2017-08-02 Issue:1 Volume:23 Page:173-180
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Matsubara Nobuaki,Nagamori Satsohi,Wakumoto Yoshiaki,Uemura Hirotsugu,Kimura Go,Yokomizo Akira,Kikukawa Hiroaki,Mizokami Atsushi,Kosaka Takeo,Masumori Naoya,Kawasaki Yoshihide,Yonese Junji,Nasu Yasutomo,Fukasawa Satoshi,Sugiyama Takayuki,Kinuya Seigo,Hosono Makoto,Yamaguchi Iku,Tsutsui Hirokazu,Uemura Hiroji

Funder

Bayer HealthCare

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/article/10.1007/s10147-017-1176-0/fulltext.html

Reference22 articles.

1. Bubendorf L, Schopfer A, Wagner U et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578–583

2. Armstrong AJ, Tannock IF, de Wit R et al (2010) The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 46:517–525

3. Sathiakumar N, Delzell E, Morrisey MA et al (2011) Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis 14:177–183